Perifosine: Phase I data

Perifosine has Orphan Drug designation in the U.S. to treat neuroblastoma. In May, Aeterna and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX, New York, N.Y.) mutually terminated a deal that gave Keryx North American rights to perifosine. Keryx is still eligible for low single-digit royalties on sales of perifosine in North America. Aeterna said it will continue a Phase III trial of perifosine in multiple myeloma (MM) (see BioCentury, May 14). Yakult has rights to perifosine in Japan, while Handok has rights in South Korea. Perifosine has Fast Track designation in the U.S. to treat advanced refractory colorectal cancer. ...